Literature DB >> 2822824

Effect of treatment with hydrochlorothiazide on the red cell Na,K-adenosine triphosphatase in men with hypertension.

A P Quintanilla1, M Finn, M I Weffer, F Del Greco.   

Abstract

We studied the effect of hydrochlorothiazide, 50 mg daily, on Na,K-adenosine triphosphatase (ATPase) activity in the red cells of 10 black men with hypertension. We also examined net sodium and potassium movement in sodium-loaded, potassium-depleted, red cells. Treatment with hydrochlorothiazide resulted in a significant increase in mean ouabain-sensitive ATPase activity (+/- SEM) from 118.4 +/- 14.6 to 158.1 +/- 15.3 nmol phosphate released per milligram of protein (P = 0.0004). Ouabain-resistant ATPase did not change. Net sodium extrusion rose significantly, from 1.62 +/- 0.27 to 2.32 +/- 0.33 mmol/L/hr (P = 0.0275). We postulate that the enhanced activity of the Na,K pump results from the volume contraction induced by the diuretic. This interpretation is consistent with the concept that the Na,K pump is inhibited in volume expansion and volume-expanded hypertension. The finding of enhanced pump activity in subjects given treatment with hydrochlorothiazide suggests a possible mechanism of the antihypertensive action of diuretic therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822824

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  3 in total

Review 1.  Digitalislike circulating factor in hypertension: potential messenger between salt balance and intracellular sodium.

Authors:  F J Haddy
Journal:  Cardiovasc Drugs Ther       Date:  1990-03       Impact factor: 3.727

Review 2.  Diuretics and cation transport in hypertensive blacks.

Authors:  A P Quintanilla; O E Wagener
Journal:  Cardiovasc Drugs Ther       Date:  1990-03       Impact factor: 3.727

3.  Evidence for a direct and non-receptor-mediated action of 5HT2 antagonists on transmembrane cation transport systems.

Authors:  L A Sechi; R Tedde; L Cassisa; A Pala; A Marigliano; S Masia; A Melis
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.